{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:23:30Z","timestamp":1790234610925,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium fr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,3,24]]},"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>There is some evidence that non-steroidal anti-inflammatory drugs (NSAIDs), in particular celecoxib, might possess not only a symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS), retarding the progression of structural damage in the spine if taken continuously. In contrast, this remains controversial for tumour necrosis factor alpha (TNF-\u03b1) inhibitors, despite their good clinical efficacy. The impact of a combined therapy (a TNF inhibitor plus an NSAID) on radiographic spinal progression in AS is unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The aim of this study is to evaluate the impact of treatment with an NSAID (celecoxib) when added to a TNF inhibitor (golimumab) compared with TNF inhibitor (golimumab) alone on progression of structural damage in the spine over 2\u2009years in patients with AS. The study consists of a 6-week screening period, a 12-week period (phase I: run-in phase) of treatment with golimumab for all subjects followed by a 96-week controlled treatment period (phase II: core phase) with golimumab plus celecoxib versus golimumab alone, and a safety follow-up period of 4 weeks. At week 108, the primary study endpoint radiographic spinal progression (as assessed by the change in the modified Stoke Ankylosing Spondylitis Spine Score after 2\u2009years) will be evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The study will be performed according to the principles of good clinical practice and the German drug law. The written approval of the independent ethics committee and of the German federal authority have been obtained. On study completion, results are expected to be published in a peer-reviewed journal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>ClinicalTrials.gov register (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02758782\">NCT02758782<\/jats:ext-link>) and European Union Clinical Trials Register (EudraCT No 2016-000615-33).<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2016-014591","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T00:10:17Z","timestamp":1497139817000},"page":"e014591","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) \u2013 an open-label randomized controlled multicenter trial"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02758782","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fabian","family":"Proft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Muche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Listing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Rios-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,6,10]]},"reference":[{"key":"2024051612135265000_7.6.e014591.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"2024051612135265000_7.6.e014591.2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024051612135265000_7.6.e014591.3","doi-asserted-by":"crossref","unstructured":"Sieper J , Poddubnyy D . Axial spondyloarthritis. Lancet 2017.doi:10.1016\/S0140-6736(16)31591-4","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2024051612135265000_7.6.e014591.4","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200007000-00002"},{"key":"2024051612135265000_7.6.e014591.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091793"},{"issue":"4 Suppl 55","key":"2024051612135265000_7.6.e014591.6","first-page":"S118","article-title":"Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Franke","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2024051612135265000_7.6.e014591.7","doi-asserted-by":"crossref","unstructured":"van der Heijde D , Ramiro S , Landew\u00e9 R , et al . 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017 2017.doi:10.1136\/annrheumdis-2016-210770","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2024051612135265000_7.6.e014591.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052878"},{"key":"2024051612135265000_7.6.e014591.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019174"},{"key":"2024051612135265000_7.6.e014591.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054098"},{"key":"2024051612135265000_7.6.e014591.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2024051612135265000_7.6.e014591.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.21054"},{"key":"2024051612135265000_7.6.e014591.13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1089\/scd.2009.0393","article-title":"The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells","volume":"19","author":"Yoon","year":"2010","journal-title":"Stem Cells Dev"},{"key":"2024051612135265000_7.6.e014591.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201370"},{"key":"2024051612135265000_7.6.e014591.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.33465"},{"key":"2024051612135265000_7.6.e014591.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"2024051612135265000_7.6.e014591.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207897"},{"key":"2024051612135265000_7.6.e014591.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.23471"},{"key":"2024051612135265000_7.6.e014591.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.23901"},{"key":"2024051612135265000_7.6.e014591.20","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"2024051612135265000_7.6.e014591.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203075"},{"key":"2024051612135265000_7.6.e014591.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202698"},{"key":"2024051612135265000_7.6.e014591.23","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"suppl 10","key":"2024051612135265000_7.6.e014591.24","first-page":"1275","article-title":"The effect of TNF inhibition on Radiographic Progression in Ankylosing Spondylitis: an Observational Cohort Study of 374 patients","volume":"67","author":"Maksymowych","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024051612135265000_7.6.e014591.25","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0481-5"},{"issue":"Suppl 10","key":"2024051612135265000_7.6.e014591.26","first-page":"2481","article-title":"High dose nonsteroidal Anti-Inflammatory drugs (NSAIDs) and tumor necrosis factor Inhibitor Use results in less radiographic progression in Ankylosing Spondylitis \u2013 a Longitudinal Analysis [abstract]","volume":"68","author":"Gensler","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024051612135265000_7.6.e014591.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"key":"2024051612135265000_7.6.e014591.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2024051612135265000_7.6.e014591.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-014591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T19:31:16Z","timestamp":1715887876000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-014591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,10]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1136\/bmjopen-2016-014591"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-014591","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}